Posted by Michael Wonder on 28 Jun 2026
Highlights from the 22-25 June 2026 CHMP meeting
26 June 2026 - The EMA’s CHMP recommended six medicines for approval at its June 2026 meeting.
The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated), a vaccine to protect people aged 50 years and older against influenza.
